keyword
https://read.qxmd.com/read/29533955/humanized-exposures-of-a-%C3%AE-lactam-%C3%AE-lactamase-inhibitor-tazobactam-versus-non-%C3%AE-lactam-%C3%AE-lactamase-inhibitor-avibactam-with-or-without-colistin-against-acinetobacter-baumannii-in-murine-thigh-and-lung-infection-models
#61
COMPARATIVE STUDY
Marguerite L Monogue, George Sakoulas, Victor Nizet, David P Nicolau
β-lactam-β-lactamase inhibitors (BLIs) have previously demonstrated antimicrobial activity against Acinetobacter baumannii (AB). Colistin retains the highest susceptibility rate against A. baumannii, and has demonstrated synergy with other antimicrobials, including β-lactam-BLIs. Therefore, we assessed the potential individual activity and synergistic combinations in vivo against carbapenem-susceptible (CS) and multidrug-resistant (MDR) A. baumannii isolates in neutropenic thigh and lung infection models...
2018: Pharmacology
https://read.qxmd.com/read/29337066/listeria-monocytogenes-endocarditis-case-report-review-of-the-literature-and-laboratory-evaluation-of-potential-novel-antibiotic-synergies
#62
REVIEW
Monika Kumaraswamy, Carter Do, George Sakoulas, Poochit Nonejuie, Guan Woei Tseng, Helen King, Joshua Fierer, Joe Pogliano, Victor Nizet
Endocarditis is a rare but serious manifestation of Listeria monocytogenes (LM). However, the optimal treatment strategy for LM endocarditis has yet to be established. Current antibiotic strategies for listeriosis include penicillin G or ampicillin (AMP) monotherapy, or AMP + gentamicin combination therapy which is often favored for endocarditis. The primary objective of our investigation was to assess the utility of AMP + ceftriaxone (CRO) and AMP + daptomycin (DAP) against LM, modeling less nephrotoxic antibiotic combinations traditionally used to manage resistant enterococcal endocarditis...
March 2018: International Journal of Antimicrobial Agents
https://read.qxmd.com/read/29244141/telavancin-for-refractory-mrsa-bacteraemia-in-intermittent-haemodialysis-recipients
#63
MULTICENTER STUDY
Nicholas S Britt, Samad Tirmizi, David J Ritchie, Jeffrey E Topal, Dayna McManus, Victor Nizet, Ed Casabar, George Sakoulas
BACKGROUND: Patients with end-stage renal disease (ESRD) requiring intermittent haemodialysis (IHD) are at high risk of MRSA bacteraemia (MRSA-B) and often fail first-line therapy. The safety, effectiveness and optimal dosing of telavancin for MRSA-B in this patient population are unclear. OBJECTIVES: We aimed to describe clinical outcomes of telavancin in the treatment of refractory MRSA-B in patients with ESRD requiring IHD. PATIENTS AND METHODS: This was a retrospective study of hospitalized patients at two tertiary care academic medical centres with recurrent or persistent (≥3 days) MRSA-B treated with telavancin monotherapy...
March 1, 2018: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/29242830/interaction-of-antibiotics-with-innate-host-defense-factors-against-salmonella-enterica-serotype-newport
#64
JOURNAL ARTICLE
George Sakoulas, Monika Kumaraswamy, Armin Kousha, Victor Nizet
This study examines the pharmacodynamics of antimicrobials that are used to treat Salmonella with each other and with key components of the innate immune system. Antimicrobial synergy was assessed using time-kill and checkerboard assays. Antimicrobial interactions with innate immunity were studied by employing cathelicidin LL-37, whole-blood, and neutrophil killing assays. Ceftriaxone and ciprofloxacin were found to be synergistic in vitro against Salmonella enterica serotype Newport. Ceftriaxone, ciprofloxacin, and azithromycin each demonstrated synergy with the human cathelicidin defense peptide LL-37 in killing Salmonella ...
November 2017: MSphere
https://read.qxmd.com/read/29020207/dissecting-out-the-direct-impacts-of-large-scale-antimicrobial-stewardship-interventions-on-clinical-outcomes-can-confounding-be-overcome
#65
JOURNAL ARTICLE
Thomas J Dilworth, Warren E Rose, George Sakoulas, Arnold S Bayer
No abstract text is available yet for this article.
July 29, 2017: Clinical Infectious Diseases
https://read.qxmd.com/read/29020165/reply-to-dilworth-rose-sakoulas-and-bayer
#66
JOURNAL ARTICLE
Eric Wenzler, Fei Wang, Debra A Goff, Beth Prier, John Mellett, Julie E Mangino, Karri A Bauer
No abstract text is available yet for this article.
July 29, 2017: Clinical Infectious Diseases
https://read.qxmd.com/read/28205673/increased-endovascular-staphylococcus-aureus-inoculum-is-the-link-between-elevated-serum-interleukin-10-concentrations-and-mortality-in-patients-with-bacteremia
#67
JOURNAL ARTICLE
Warren E Rose, Sanjay K Shukla, Andrew D Berti, Mary S Hayney, Kelsey M Henriquez, Andrea Ranzoni, Matthew A Cooper, Richard A Proctor, Victor Nizet, George Sakoulas
BACKGROUND: Cell wall peptidoglycan stimulates interleukin 10 (IL-10) production in Staphylococcus aureus bacteremia (SaB) animal models, but clinical data are not available. This study evaluates the impact of intravascular bacterial cell numbers (ie, the level of bacteremia), in patients at the time of clinical presentation on IL-10 production and its association with S. aureus bacteremia (SaB) mortality. METHODS: Blood and isolates were collected in 133 consecutive SaB patients...
May 15, 2017: Clinical Infectious Diseases
https://read.qxmd.com/read/28069650/evidence-to-support-continuation-of-statin-therapy-in-patients-with-staphylococcus-aureus-bacteremia
#68
JOURNAL ARTICLE
Aisling R Caffrey, Tristan T Timbrook, Eunsun Noh, George Sakoulas, Steven M Opal, Victor Nizet, Kerry L LaPlante
In addition to cholesterol-lowering capabilities, statins possess anti-inflammatory and immunomodulatory effects. We sought to quantify the real-world impact of different statin exposure patterns on clinical outcomes in Staphylococcus aureus bacteremia. We conducted a retrospective cohort study among hospitalized patients with positive S. aureus blood cultures receiving appropriate antibiotics within 48 h of culture collection (Veterans Affairs hospitals, 2002 to 2013). Three statin exposure groups were compared to nonusers: pretreated statin users initiating therapy in the 30 days prior to culture and either (i) continuing statin therapy after culture or (ii) not continuing after culture, and (iii) de novo users initiating at culture...
March 2017: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/27872080/classical-%C3%AE-lactamase-inhibitors-potentiate-the-activity-of-daptomycin-against-methicillin-resistant-staphylococcus-aureus-and-colistin-against-acinetobacter-baumannii
#69
JOURNAL ARTICLE
George Sakoulas, Warren Rose, Andrew Berti, Joshua Olson, Jason Munguia, Poochit Nonejuie, Eleanna Sakoulas, Michael J Rybak, Joseph Pogliano, Victor Nizet
We asked whether beta-lactamase inhibitors (BLIs) increased the activity of daptomycin (DAP) against methicillin-resistant Staphylococcus aureus (MRSA), the peptide antibiotic colistin (COL) against the emerging Gram-negative nosocomial pathogen Acinetobacter baumannii, and the human host defense peptide cathelicidin LL37 against either pathogen. DAP and LL37 kill curves were performed with or without BLIs against MRSA, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA (hVISA). COL and LL37 kill curves were performed against A...
February 2017: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/27821441/%C3%AE-lactamase-inhibitors-enhance-the-synergy-between-%C3%AE-lactam-antibiotics-and-daptomycin-against-methicillin-resistant-staphylococcus-aureus
#70
JOURNAL ARTICLE
Karl Evans R Henson, Juwon Yim, Jordan R Smith, George Sakoulas, Michael J Rybak
The evidence for using combination therapy for the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections is growing. In this study, we investigated the synergistic effect of daptomycin (DAP) combined with piperacillin-tazobactam and ampicillin-sulbactam against MRSA in time-kill experiments. Six of eight strains demonstrated synergy between DAP and the β-lactam-β-lactamase inhibitor (BLI) combination. In 5/8 strains, the synergy occurred only in the presence of the BLI, highlighting a role for BLIs in peptide-β-lactam synergy...
January 2017: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/27572414/cefazolin-and-ertapenem-a-synergistic-combination-used-to-clear-persistent-staphylococcus-aureus-bacteremia
#71
JOURNAL ARTICLE
George Sakoulas, Joshua Olson, Juwon Yim, Niedita B Singh, Monika Kumaraswamy, Diana T Quach, Michael J Rybak, Joseph Pogliano, Victor Nizet
Ertapenem and cefazolin were used in combination to successfully clear refractory methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. In addition, recent work has demonstrated activity of combination therapy with beta-lactams from different classes against methicillin-resistant S. aureus (MRSA). The ertapenem-plus-cefazolin combination was evaluated for synergy in vitro and in vivo in a murine skin infection model using an index MSSA bloodstream isolate from a patient in whom persistent bacteremia was cleared with this combination and against a cadre of well-described research strains and clinical strains of MSSA and MRSA...
November 2016: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/27431211/fosfomycin-enhances-the-activity-of-daptomycin-against-vancomycin-resistant-enterococci-in-an-in-vitro-pharmacokinetic-pharmacodynamic-model
#72
JOURNAL ARTICLE
Ashley D Hall Snyder, Brian J Werth, Poochit Nonejuie, John P McRoberts, Joe Pogliano, George Sakoulas, Juwon Yim, Nivedita Singh, Michael J Rybak
Daptomycin (DAP) is being used more frequently to treat infections caused by vancomycin-resistant enterococcus (VRE). DAP tends to be less active against enterococci than staphylococci and may require high doses or combination therapy to be bactericidal. Fosfomycin (FOF) has activity against VRE and has demonstrated synergistic bactericidal activity with DAP in vitro The objective of this study was to evaluate the activity of DAP alone and in combination with FOF against VRE in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model...
October 2016: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/27234592/effects-of-vancomycin-versus-nafcillin-in-enhancing-killing-of-methicillin-susceptible-staphylococcus-aureus-causing-bacteremia-by-human-cathelicidin-ll-37
#73
JOURNAL ARTICLE
J Le, Q Dam, M Schweizer, W Thienphrapa, V Nizet, G Sakoulas
Recent studies have demonstrated that anti-staphylococcal beta-lactam antibiotics, like nafcillin, render methicillin-resistant Staphylococcus aureus (MRSA) more susceptible to killing by innate host defense peptides (HDPs), such as cathelicidin LL-37. We compared the effects of growth in 1/4 minimum inhibitory concentration (MIC) of nafcillin or vancomycin on the LL-37 killing of 92 methicillin-susceptible S. aureus (MSSA) isolates. For three randomly selected strains among these, we examined the effects of nafcillin, vancomycin, daptomycin, or linezolid on LL-37 killing and autolysis...
September 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://read.qxmd.com/read/26994090/efficacy-of-ceftolozane-tazobactam-versus-levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections-cutis-caused-by-levofloxacin-resistant-pathogens-results-from-the-aspect-cuti-trial
#74
RANDOMIZED CONTROLLED TRIAL
Jennifer A Huntington, George Sakoulas, Obiamiwe Umeh, Daniel J Cloutier, Judith N Steenbergen, Caleb Bliss, Ellie J C Goldstein
OBJECTIVES: Empirical fluoroquinolone therapy is widely used in treating complicated urinary tract infections (cUTIs), even in areas of high fluoroquinolone resistance. While it is believed that high antibiotic concentrations in urine might be sufficient to overcome and effectively treat infections caused by resistant bacteria, clinical trial data validating this assumption are limited. This post hoc analysis evaluated the efficacy of ceftolozane/tazobactam versus levofloxacin in the subgroup of patients with cUTIs caused by levofloxacin-resistant pathogens in a randomized, controlled trial (NCT01345929/NCT01345955)...
July 2016: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/26981574/bacterial-cytological-profiling-bcp-as-a-rapid-and-accurate-antimicrobial-susceptibility-testing-method-for-staphylococcus-aureus
#75
JOURNAL ARTICLE
D T Quach, G Sakoulas, V Nizet, J Pogliano, K Pogliano
Successful treatment of bacterial infections requires the timely administration of appropriate antimicrobial therapy. The failure to initiate the correct therapy in a timely fashion results in poor clinical outcomes, longer hospital stays, and higher medical costs. Current approaches to antibiotic susceptibility testing of cultured pathogens have key limitations ranging from long run times to dependence on prior knowledge of genetic mechanisms of resistance. We have developed a rapid antimicrobial susceptibility assay for Staphylococcus aureus based on bacterial cytological profiling (BCP), which uses quantitative fluorescence microscopy to measure antibiotic induced changes in cellular architecture...
February 2016: EBioMedicine
https://read.qxmd.com/read/26832758/standard-susceptibility-testing-overlooks-potent-azithromycin-activity-and-cationic-peptide-synergy-against-mdr-stenotrophomonas-maltophilia
#76
JOURNAL ARTICLE
Monika Kumaraswamy, Leo Lin, Joshua Olson, Ching-Fang Sun, Poochit Nonejuie, Ross Corriden, Simon Döhrmann, Syed Raza Ali, Deirdre Amaro, Manfred Rohde, Joe Pogliano, George Sakoulas, Victor Nizet
OBJECTIVES: The Gram-negative bacillus Stenotrophomonas maltophilia (SM) is an emerging MDR opportunistic pathogen. Recent studies identify a potentially relevant activity of azithromycin against Gram-negative bacteria overlooked in standard bacteriological testing. We investigated azithromycin activity against SM in testing conditions incorporating mammalian tissue culture medium and host defence factors. METHODS: MIC testing, chequerboard assays, time-kill assays and fluorescence microscopy were performed for azithromycin, the cationic peptide antibiotic colistin and the human defence peptide cathelicidin LL-37 alone or in combination in cation-adjusted Mueller-Hinton broth or mammalian tissue culture media...
May 2016: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/26565015/when-sepsis-persists-a-review-of-mrsa-bacteraemia-salvage-therapy
#77
REVIEW
Ravina Kullar, George Sakoulas, Stan Deresinski, Sebastiaan J van Hal
MRSA bacteraemia (MRSAB), including infective endocarditis, carries a high mortality rate, with up to 50% of patients failing initial therapy with vancomycin and requiring salvage therapy. Persistent MRSAB can be difficult to successfully eliminate, especially when source control is not possible due to an irremovable focus or the bacteraemia still persists despite surgical intervention. Although vancomycin and daptomycin are the only two antibiotics approved by the US FDA for the treatment of patients with MRSAB as monotherapy, the employment of novel strategies is required to effectively treat patients with persistent MRSAB and these may frequently involve combination drug therapy...
March 2016: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/26525797/penicillin-binding-protein-1-is-important-in-the-compensatory-response-of-staphylococcus-aureus-to-daptomycin-induced-membrane-damage-and-is-a-potential-target-for-%C3%AE-lactam-daptomycin-synergy
#78
JOURNAL ARTICLE
Andrew D Berti, Erin Theisen, John-Demian Sauer, Poochit Nonejuie, Joshua Olson, Joseph Pogliano, George Sakoulas, Victor Nizet, Richard A Proctor, Warren E Rose
The activity of daptomycin (DAP) against methicillin-resistant Staphylococcus aureus (MRSA) is enhanced in the presence of β-lactam antibiotics. This effect is more pronounced with β-lactam antibiotics that exhibit avid binding to penicillin binding protein 1 (PBP1). Here, we present evidence that PBP1 has a significant role in responding to DAP-induced stress on the cell. Expression of the pbpA transcript, encoding PBP1, was specifically induced by DAP exposure whereas expression of pbpB, pbpC, and pbpD, encoding PBP2, PBP3, and PBP4, respectively, remained unchanged...
January 2016: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/26288841/azithromycin-synergizes-with-cationic-antimicrobial-peptides-to-exert-bactericidal-and-therapeutic-activity-against-highly-multidrug-resistant-gram-negative-bacterial-pathogens
#79
JOURNAL ARTICLE
Leo Lin, Poochit Nonejuie, Jason Munguia, Andrew Hollands, Joshua Olson, Quang Dam, Monika Kumaraswamy, Heriberto Rivera, Ross Corriden, Manfred Rohde, Mary E Hensler, Michael D Burkart, Joe Pogliano, George Sakoulas, Victor Nizet
Antibiotic resistance poses an increasingly grave threat to the public health. Of pressing concern, rapid spread of carbapenem-resistance among multidrug-resistant (MDR) Gram-negative rods (GNR) is associated with few treatment options and high mortality rates. Current antibiotic susceptibility testing guiding patient management is performed in a standardized manner, identifying minimum inhibitory concentrations (MIC) in bacteriologic media, but ignoring host immune factors. Lacking activity in standard MIC testing, azithromycin (AZM), the most commonly prescribed antibiotic in the U...
July 2015: EBioMedicine
https://read.qxmd.com/read/26195528/differential-effects-of-penicillin-binding-protein-deletion-on-the-susceptibility-of-enterococcus-faecium-to-cationic-peptide-antibiotics
#80
JOURNAL ARTICLE
George Sakoulas, Monika Kumaraswamy, Poochit Nonejuie, Brian J Werth, Micahel J Rybak, Joseph Pogliano, Louis B Rice, Victor Nizet
Beta-lactam antibiotics sensitize Enterococcus faecium to killing by endogenous antimicrobial peptides (AMPs) of the innate immune system and daptomycin through mechanisms yet to be elucidated. It has been speculated that beta-lactam inactivation of select E. faecium penicillin binding proteins (PBPs) may play a pivotal role in this sensitization process. To characterize the specific PBP inactivation that may be responsible for these phenotypes, we utilized a previously characterized set of E. faecium PBP knockout mutants to determine the effects of such mutations on the activity of daptomycin and the AMP human cathelicidin (LL-37)...
October 2015: Antimicrobial Agents and Chemotherapy
keyword
keyword
160202
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.